Inhibitec Antibodies, S.L. Cantabrian biotechnology company has developed a monoclonal antibody for a new therapeutic target

Jean-François AlandryCEO & Founder, You Are Capital

Inhibitec Antibodies, S.L. Cantabrian biotechnology company, a spin-off of the CSIC and University of Cantabria, has developed a monoclonal antibody for a new therapeutic target. Last week,  it was in Cambridge, within the Idea Spark Program designed by MIT and SODERCAN.

A significant number of psoriatic patients with the severe disease do not respond to existing therapies. A key molecule involved its pathogenic is BAMBI and its inhibition with our specific mAbs (BI0137) prevents skins and articular lesions in preclinical experimental models of psoriasis.

Contributing Advisors

Myles CulmerDirector, BDO Advisory Services